RxDoctor Payments Data

Richard White, MD

Procedural Dermatology · Rock Hill, SCNPI 1730165465

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 59 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$345
  • AbbVie$256
  • Novartis$133
  • Amgen$100
  • Sanofi$66
  • Pfizer$59
  • plus $227 from 12 others
$750in research payments, 2019–2025

Across 1 payment — averaging $750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • LEO Pharma AS$750

What the payments were for

  • Food & beverage$91977%
  • Education$26723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few procedural dermatology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$766,372
Medicare patients
2,035
Services billed
13,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast29$137,320
Metronidazole135$7,658
Doxycycline Hyclate265$7,347
Pimecrolimus13$5,945
Ketoconazole311$5,654
Doxycycline Ir-DrDoxycycline Monohydrate12$4,950
Clobetasol Propionate89$4,788
Triamcinolone Acetonide579$4,425
Dapsone21$3,463
CiclopiroxCiclopirox Olamine138$3,233
Calcipotriene21$2,407
Fluocinonide38$1,474
ValacyclovirValacyclovir Hcl12$1,164
Halobetasol Propionate23$1,131
Permethrin28$978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$100$137,32029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Rock Hill

Where these figures come from

Is this you, or does something look wrong? →